Research Site
Tilburg 5042AD
1 studies enrolling now · 31 studies all time
What they study most
Acute Coronary Syndrome, Advanced Solid Tumors, Advanced or Metastatic Non-Small Cell Lung Cancer, Anemia, Atherothrombosis, Breast Cancer, Cancer, Cardiovascular Death, Cardiovascular Disease, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, Coronary Heart Disease (CHD)
Studies at this site
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 — Recruiting now
- Phase IIa Study Evaluating AZD7798 in Crohn's Disease — Running, not enrolling
- A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. — Running, not enrolling
- A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy — Running, not enrolling
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer — Running, not enrolling
- Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency — Running, not enrolling
- Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) — Running, not enrolling
- A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 — Completed
- Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction — Completed
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
- A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer — Completed
- Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) — Completed
- Dimethyl Fumarate (DMF) Observational Study — Completed
- Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy — Stopped early
- RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial — Completed
- Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS — Completed
- Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
- Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer — Completed
- Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) — Stopped early
- Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia — Completed
- A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors — Completed
- Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 — Completed
- Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia — Completed
- Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab — Completed
- GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound — Completed
- Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin — Completed
- Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) — Completed
- JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events — Stopped early
- A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer — Stopped early
- A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome — Completed
- A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients — Completed